SU997084A1 - Method of simulating peritonitis - Google Patents

Method of simulating peritonitis Download PDF

Info

Publication number
SU997084A1
SU997084A1 SU813278177A SU3278177A SU997084A1 SU 997084 A1 SU997084 A1 SU 997084A1 SU 813278177 A SU813278177 A SU 813278177A SU 3278177 A SU3278177 A SU 3278177A SU 997084 A1 SU997084 A1 SU 997084A1
Authority
SU
USSR - Soviet Union
Prior art keywords
peritonitis
simulating
suspension
feces
appendicitis
Prior art date
Application number
SU813278177A
Other languages
Russian (ru)
Inventor
Николай Никифорович Казначеев
Галина Петровна Рослякова
Original Assignee
Курский Государственный Медицинский Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Курский Государственный Медицинский Институт filed Critical Курский Государственный Медицинский Институт
Priority to SU813278177A priority Critical patent/SU997084A1/en
Application granted granted Critical
Publication of SU997084A1 publication Critical patent/SU997084A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Изобретение относитс  к медицине, а именно к способам получени  моделей перитонита дл  изучени  егр развити , течени  и лечени .The invention relates to medicine, in particular, to methods for producing models of peritonitis for the study of the rate of development, course and treatment.

Известен способ моделировани  перитонита путем введени  30%-ной суспензии кала в бркшную полость tlj.There is a known method for simulating peritonitis by introducing a 30% fecal suspension into the tumor cavity tlj.

Однако при Применении известного способа попадание патогенного раздражител  в полость брюшины приводит к шоковой, реакции и гибели животных, а введение суспензии кала собаки, где реакци  микрофлоры на лекарственные препараты недостаточно исследована, затрудн ет изучение йеритонита в услови х- медикоментозной терапии.However, when using a known method, the penetration of a pathogenic irritant into the peritoneal cavity leads to shock, reaction and death of animals, and the introduction of a dog feces suspension, where the response of microflora to drugs is insufficiently investigated, makes it difficult to study yeritonitis under conditions of medication and chemotherapy.

Целью изобретени   вл етс  приближение искусственной патологии к клиническому течению заболевани  у человека , адекватному осложнению аппендицита и холецистита..The aim of the invention is the approximation of an artificial pathology to the clinical course of the disease in humans, adequate to the complication of appendicitis and cholecystitis ..

Цель достигаетс  -тем, что при мо;делировании перитонита путем введени  30%-нЬй суспензии кала в брюшную полость суспензию кала ввод т в дозе 1-2 мл/кг веса животного в толщу па риетальной бркшины .и в предбришинную клетчатку. The goal is achieved by the fact that when modeling peritonitis by introducing a 30% suspension of feces into the abdominal cavity, the suspension of feces is administered at a dose of 1-2 ml / kg of animal weight into the thickness of the respiratory tissue.

Способ осуществл ют следующим образом .The method is carried out as follows.

В r v6oKHe слои брюшины и предбрют In r v6oKHe layers of peritoneum and prebryut

шинную клетчатку н шне-боковыз сте-. нок живота животного, например собаки , на фоне измененной реактивности . организма ввод т патогенный раздражитель , HanpHfdep суспензию кала человека . Вводима  доза составл ет .1-2 мл на 1 кг веса животного. А дл  предупреждени  возможной перфорации tire tissue n shne-bozor st. Nok stomach animal, such as dogs, on the background of altered reactivity. pathogenic stimulus, HanpHfdep human feces suspension is administered to the body. The injected dose is. 1-2 ml per kg of animal weight. And to prevent possible perforation

10 бргалины стенку животного послойно .: : рассекают до серозного покрова и под,. контролем зрени  30%-ную суспензию -: ввод т иглой в толщину брюшины и10 brgalina animal wall layers.:: Cut through to the serous cover and under ,. vision control 30% suspension -: injected with a needle into the thickness of the peritoneum and

предбркшинную клетчаткуi .pre-breakthrough fiber.

1515

При введении патогенного раздражител  создаютс  услови , идентичные возникновению перитонита, которым ос;-; ложнились аппендицит и холецистит у человека. Дл  преду1 ре)|здени  возник 20 новени  болевого шока и перитонналь ного сепсиса патогенный раздражитель ввод т не в полость бркшины, а локализуют в предбрмшинной клетчатке и глубоких сло х брюшины на ограничен25 ном участке ее и он не вызывает инт .енсивнох о раздражени  рецепторного аппарата серозного покрова. При аппендиците и холецистите, осложнив ,шихс  перитонитом, воспалительный  With the introduction of a pathogenic stimulus, conditions are created that are identical to the occurrence of peritonitis with which os; -; lied appendicitis and cholecystitis in humans. To prevent the development of painful shock and peritoneal sepsis, the pathogenic stimulus is not introduced into the cavity of the brain, but is localized in the prebarum tissue and the deep layers of the peritoneum in a limited part of it and does not cause intense irritation of the receptor apparatus. serous cover. When appendicitis and cholecystitis, complicating, aggravated peritonitis, inflammatory

30 процес р сначала-локализуетс  в ели30 process is first localized in spruce

Claims (1)

Формула изобретенияClaim Способ моделирования перитонита путем введения 30%-ной суспензии кала в брюшную полость, о т л и ч а тощи й с я тем, что, с целью приближения искусственной патологии к клиническому течению заболевания у человека, адекватному осложнению аппендицита и холецистита, суспензию кала вводят в дозе 1-2 мл/кг веса животного в толщу париетальной брюшины и в прёдбрюшинную клетчатку.A method for simulating peritonitis by introducing a 30% feces suspension into the abdominal cavity, which is so simple because in order to bring the artificial pathology closer to the clinical course of the disease in humans, adequate to complicate appendicitis and cholecystitis, the feces suspension is administered at a dose of 1-2 ml / kg of animal weight into the thickness of the parietal peritoneum and into the peritoneal fiber.
SU813278177A 1981-04-27 1981-04-27 Method of simulating peritonitis SU997084A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU813278177A SU997084A1 (en) 1981-04-27 1981-04-27 Method of simulating peritonitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU813278177A SU997084A1 (en) 1981-04-27 1981-04-27 Method of simulating peritonitis

Publications (1)

Publication Number Publication Date
SU997084A1 true SU997084A1 (en) 1983-02-15

Family

ID=20954272

Family Applications (1)

Application Number Title Priority Date Filing Date
SU813278177A SU997084A1 (en) 1981-04-27 1981-04-27 Method of simulating peritonitis

Country Status (1)

Country Link
SU (1) SU997084A1 (en)

Similar Documents

Publication Publication Date Title
Beach Morphine addiction in rats.
Jansen The ketamine model of the near-death experience: A central role for the N-methyl-D-aspartate receptor
FORRER et al. Atropine coma: a somatic therapy in psychiatry
Whitehouse Effects of atropine on discrimination learning in the rat.
US3484521A (en) Enhancement of memory processes in mammals with basic addition salts of ribonucleic acid
Smith The characteristics of dependence in high-dose methamphetamine abuse
SU997084A1 (en) Method of simulating peritonitis
Yoxall Pain in small animals–its recognition and control
Funderburk et al. Effect of parasympathetic drugs on the conditioned response
Phillips et al. Blockade of sensitisation-induced facilitation of appetitive conditioning by post-session intra-amygdala nafadotride
CN112569237B (en) Application of combination or compound of imatinib and derivatives thereof and nicotine or analogues thereof in preventing and treating nicotine addiction and relapse
Helmstetter et al. The beta-carboline DMCM produces hypoalgesia after central administration
RU2151427C1 (en) Method for modeling acute peritonitis
Maier et al. Dissociation of interference with the speed and accuracy of escape produced by inescapable shock.
McCrindle, Cheryl ME, Ebedes, H. & Swan The use of long-acting neuroleptics, perphenazine enanthate and pipothiazine palmitate in two horses
OSBORNE et al. The effect of arsenic on rabbits: Microchemical studies following the administration of the arsphenamines and tryparsamide
SU1767518A1 (en) Method for simulating hemorrhagic cerebral thrombosis
O'brien et al. Preparation of injectable dantrolene for emergency treatment of malignant hyperthermia-like syndromes
Kasckow et al. Performance factors in regard to impaired memory and tolerance induced by atropine sulfate
SU1629916A1 (en) Method of modelling diabetes mellitus
SU1545243A1 (en) Method of simulating peritonitis
SU1562953A1 (en) Method of modeling psychomotor paroxysms
SU1506472A1 (en) Method of simulating pathological scratching reflex
Green et al. Effects of centrifugal rotation on analgesia and conditioned flavor aversions
CN101632653A (en) BAPTA and application of derivant thereof in preparing analgesic drugs